Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies announced a leadership change with
NanoString Technologies (NASDAQ:NSTG) reported record Q4 2021 revenue of
NanoString Technologies (NASDAQ:NSTG) will present at the 40th Annual JP Morgan Healthcare Conference from January 10-13, 2022. CEO Brad Gray is scheduled to speak on January 12, 2022, at 3:00 PM PT. The presentation will be available via live webcast on the company's investor website, with a replay accessible one hour after the presentation and archived for 60 days. NanoString is recognized for its innovative life science tools, enabling advanced research such as the nCounter Analysis System and GeoMx Digital Spatial Profiler, among others.
NanoString Technologies, Inc. (NASDAQ:NSTG) announced its participation in the Stifel 2021 Virtual Healthcare Conference. CEO Brad Gray will present on November 15, 2021, at 4:40 PM ET. The live webcast, including slides, will be accessible via the investor section of their website at www.nanostring.com. A replay will be available one hour post-presentation and archived for 60 days. NanoString is known for its innovative life science tools, including the nCounter® Analysis System and GeoMx® Digital Spatial Profiler.
NanoString Technologies, Inc. (NASDAQ:NSTG) reported Q3 financial results for the period ending September 30, 2021, with product and service revenue of $36.9 million, a 23% year-over-year increase. Instrument revenues grew 13% to $14.5 million, while consumables revenue surged 32% to $18.0 million. The GeoMx DSP revenues reached $49 to $50 million in 2021, exceeding prior guidance. Despite growth, net loss for Q3 was $31.3 million. The company aims to bolster its market position with innovative Spatial Biology technologies like CosMx SMI.
NanoString Technologies (NASDAQ: NSTG) recently announced a significant peer-reviewed study published in Cell, exploring anosmia, a COVID-19 symptom. The research analyzed 70 patient samples to determine the impact of SARS-CoV-2 on olfactory neurons using the GeoMx Digital Spatial Profiler. Findings revealed that while the virus does not directly infect olfactory sensory neurons, high viral loads reduce gene expression in neighboring cells. This research underscores the utility of spatial transcriptomics in understanding COVID-19's effects, marking a notable advancement in the field of life sciences.
Vizgen has appointed Dale Levitzke as Senior Vice President of Global Sales and Support, aiming to enhance its commercial reach for the MERSCOPE Platform.
Levitzke, with nearly 20 years in diagnostics sales, previously led NanoString's revenue growth from under $10MM to over $125MM. His experience will help Vizgen navigate the global market and expand distribution channels in 2022.
The MERSCOPE Platform offers significant insights into spatial genomics, with early uptake at leading institutions, reflecting strong demand in the burgeoning field of spatial biology.
NanoString Technologies (NASDAQ: NSTG) has launched the Spatial Organ Atlas, a vital resource that maps spatially resolved whole transcriptomes from six organs, including the kidney and pancreas. This initiative aims to provide researchers with insights into organ functions in health and disease, enhancing the utility of the GeoMx® Digital Spatial Profiler. The database is publicly accessible, offering downloadable datasets, interactive tools, and plans for continuous updates to include additional organs.
NanoString Technologies, a leader in life science tools, has launched the nCounter® ADC Development Panel to facilitate research in Antibody Drug Conjugates (ADCs). This new gene expression tool, developed with input from pharmaceutical experts, aims to provide comprehensive molecular insights necessary for addressing critical questions in oncology therapies. The panel can profile 770 genes and aids in understanding ADC mechanisms, including tumor targeting and resistance. Currently, there are 10 approved ADCs and over 80 in clinical trials, indicating the growing importance of this technology in cancer treatment.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
